Free Trial
NASDAQ:XFOR

X4 Pharmaceuticals Q3 2026 Earnings Results & Report

X4 Pharmaceuticals logo
$3.12 -0.05 (-1.58%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$3.12 0.00 (-0.16%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

X4 Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$0.16 versus the -$0.1680 consensus estimate, while revenue of $2.88 million topped the $2.78 million estimate by $99.00 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes
Conference Call Date
Conference Call
7:00 AM ET

X4 Pharmaceuticals EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.1680
Beat/Miss
Beat by +$0.0080
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

X4 Pharmaceuticals Revenue Results

Actual Revenue
$2.88 million
Expected Revenue
$2.78 million
Beat/Miss
Beat by +$99.00 thousand
YoY Revenue Growth
N/A

X4 Pharmaceuticals Q3 2026 Earnings FAQ

X4 Pharmaceuticals (NASDAQ:XFOR) reported earnings of -$0.16 per share for Q3 2026, beating the consensus estimate of -$0.1680. The report was announced on Thursday, November 5, 2026.

X4 Pharmaceuticals reported revenue of $2.88 million for Q3 2026, against a consensus estimate of $2.78 million.

X4 Pharmaceuticals Earnings Headlines

Brookline Capital Markets Comments on XFOR FY2030 Earnings
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.tc pixel
X4 Pharmaceuticals (XFOR) Projected to Announce Earnings on Wednesday
See More X4 Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like X4 Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on X4 Pharmaceuticals and other key companies, straight to your email.

About X4 Pharmaceuticals

X4 Pharmaceuticals (NASDAQ:XFOR) is a biopharmaceutical company focused on developing treatments for rare diseases involving dysfunction of the CXCR4 receptor, which plays a role in the movement of immune cells in the body.

Its lead medicine, mavorixafor, is marketed in the United States as Xolremdi. The U.S. Food and Drug Administration approved it in 2024 for people aged 12 and older with WHIM syndrome, a rare inherited condition that can leave patients vulnerable to infections.

X4 has also studied mavorixafor for other conditions associated with low levels of certain blood cells, including chronic neutropenia. The company’s work has centered on therapies that target CXCR4 to help improve immune-cell circulation.

View X4 Pharmaceuticals Profile